Physician

Aroti Hegde, M.D.

According to 2025 Medicare claims, Aroti Hegde, M.D. (NPI: 1033164785) practices nephrology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from The District, DC. This provider's primary affiliated billing organization is NATIONAL CAPITAL NEPHROLOGY, PC (NPI: 1912177049; TIN: 010767477) and primary practice location at 20010-3017.

Hegde's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,106 traditional Medicare patients, billed 5,830 HCPCS/CPT codes, and received $726,099 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,792 prescription claims across 691 beneficiaries totaling $843,487 in drug costs, led by Jardiance (Empagliflozin). DME data shows 91 claims. Open Payments data shows 17 records totaling $13,392. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $949,290 to $843,487. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,524 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,301	7,892	$760,521
2016	1,334	8,015	$746,840
2017	1,431	8,585	$832,532
2018	1,451	9,505	$954,312
2019	1,286	8,026	$938,912
2020	1,188	7,830	$922,526
2021	1,158	7,020	$975,580
2022	1,027	5,696	$841,179
2023	1,125	6,409	$775,822
2024	1,106	5,830	$726,099

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	358	5,242	$949,290
2016	379	5,601	$1,184,305
2017	400	5,829	$1,458,375
2018	429	4,984	$736,243
2019	428	3,526	$516,767
2020	432	3,587	$502,563
2021	445	3,935	$664,368
2022	461	3,631	$582,018
2023	524	3,574	$930,451
2024	691	3,792	$843,487

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	283	$19,334
2016	35	435	$19,036
2017	55	484	$21,610
2018	58	580	$31,692
2019	59	600	$21,578
2020	64	557	$22,604
2021	57	590	$19,725
2022	46	440	$11,823
2023	31	283	$7,280
2024	N/R	91	$1,825

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	207	238	$155
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	146	169	$119
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	329	1,936	$72
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	566	1,309	$70
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	151	184	$69

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	200	8,823	$157,373
Farxiga	Dapagliflozin Propanediol	181	8,344	$132,163
Velphoro	Sucroferric Oxyhydroxide	32	1,020	$114,786
Veltassa	Patiromer Calcium Sorbitex	33	1,528	$42,259
Kerendia	Finerenone	40	1,570	$33,867

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	34	$961
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$393
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$251
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	13	$221

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$13,392	Nuwellis, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aroti Hegde, M.D.?

Tedicare shows public-source Medicare data for Aroti Hegde, M.D. (NPI 1033164785), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aroti Hegde, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aroti Hegde, M.D.?

Aroti Hegde, M.D. is linked to NATIONAL CAPITAL NEPHROLOGY, PC (billing NPI 1912177049) in the available physician profile data.

Does Aroti Hegde, M.D. have Open Payments data?

Aroti Hegde, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.